- In May 2024, Pfizer Inc. initiated a clinical collaboration with leading cardiovascular centers in North America to evaluate the efficacy of next-generation broad-spectrum antibiotics in the treatment of deep sternal wound infections, including mediastinitis. This initiative reflects Pfizer’s commitment to combatting post-surgical infections through innovation and precision antimicrobial therapies, aiming to reduce recovery times and hospital readmissions for cardiac surgery patients
- In April 2024, 3M Health Care expanded its wound care portfolio by launching a new range of antimicrobial incise drapes and negative pressure wound therapy (NPWT) systems, designed specifically to prevent and manage complex surgical infections such as mediastinitis. These products offer improved postoperative outcomes by reducing microbial contamination at incision sites, reinforcing 3M’s leadership in advanced surgical site infection (SSI) prevention technologies
- In March 2024, Abbott Laboratories announced the results of a multicenter study evaluating the use of rapid diagnostic testing for early detection of mediastinitis in high-risk cardiac surgery patients. The study showed significant improvement in early intervention outcomes, supporting the integration of point-of-care molecular diagnostics in postoperative care protocols. Abbott’s innovation aims to enhance clinical decision-making and minimize complications associated with delayed diagnosis
- In February 2024, Medtronic plc launched an awareness campaign in partnership with global cardiac surgery associations to educate healthcare professionals about best practices in mediastinitis prevention and management. The initiative emphasizes the role of surgical technique, glycemic control, and optimized antimicrobial use in reducing infection rates, showcasing Medtronic’s focus on holistic, patient-centered care strategies
- In January 2024, BD (Becton, Dickinson and Company) unveiled its new antimicrobial sternal closure system aimed at reducing infection risks in open-heart surgeries. Designed to inhibit microbial colonization while ensuring secure wound closure, this product highlights BD’s commitment to advancing infection control technologies and supporting improved outcomes for patients susceptible to mediastinitis
